Targeting context-specific estrogen receptor complexes to treat lobular breast cancer

Active Grant Awarded Last action

Award ID
R21CA307898
Recipient
Awarding agency
Obligated
$417,074

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 18% complete
Place of performance
Aurora, CO 80045, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Grant R21CA307898 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, with $417,074 obligated on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395). The research targets context-specific estrogen receptor complexes to treat lobular breast cancer. The abstract argues that invasive lobular carcinoma patients have worse long-term outcomes than invasive ductal carcinoma patients because many SERMs and SERDs act as weak estrogens in lobular cells. It also reports that genetic ablation of lobular-specific estrogen receptor co-regulators resensitized lobular cancer cells to tamoxifen. The period of performance runs from the July 13, 2026 award date to the June 30, 2028 ultimate completion date. Place of performance is Aurora, Colorado 80045.

Loyola University of Chicago's Health Sciences Campus received a sub-award under this grant, designated R21CA307898-FY27.1272.001, dated August 4, 2026. The sub-award carries the same lobular breast cancer research description.

Description

Abstract
Abstract invasive lobular carcinomas (ILCS), the most common special histopathological subtype of breast cancer, have significantly worse long-term outcomes than invasive ductal carcinomas (idcs, i.e. breast cancer of no special type). Estrogen receptor alpha (ER), the foremost therapeutic target in this setting, is highly expressed in most ILCS and idcs, yet only IDC patients benefit from the full pharmacologic range of ER-targeting endocrine therapies, specifically selective estrogen receptor modulators (SERMS) and degraders/downregulators (SERDS). ER is targeted because, as a ligand-dependent master transcriptional regulator, IT coordinates oncogenic processes critical to tumor growth, survival, and metastasis, which are transcriptionally activated by the formation of ligand-specific ER:CO-regulator complexes. However, CO-regulator proteins show tissue context-specific expression patterns that alter serm/D pharmacology. For example, tamoxifen, a serm, is anti-proliferative in the breast epithelium and IDC, but acts as a weak estrogen in the uterus due to differential expression of CO-regulators within the endometrium. Critically, we find many serm/DS including next-GEN SERDS act as weak estrogens that promote the proliferation of ILC cells, limiting the clinical utility of these endocrine therapies for patients with ILC and potentially explaining the poor long-term outcomes associated with ILC. Our work shows that, while tamoxifen and estrogen (17Β-estradiol, E2) each drive different ER:CO- regulator interactions in IDC cells, tamoxifen versus E2 CO-regulator profiles are nearly identical in ILC cells. Importantly, genetic ablation of ILC-specific ER CO-regulators suppressed ER activity and resensitized ILC cells to tamoxifen. Therefore, the switch from anti-estrogenic (in IDC) to weak estrogenic profiles (in ILC) likely depends on the formation of unique ER:CO-regulator complexes in ILC cells. Based on our preliminary studies, we hypothesize that inhibition of ILC-specific key ER:CO-regulator complexes will overcome pharmacologic endocrine therapy resistance in ILC. To test this hypothesis we will pursue two specific aims. In specific aim 1 a high-throughput assay will be employed to identify novel serm/DS that disrupt the association between ER and validated ILC-specific CO-regulators (MDC1, AKAP9, NCOA5, TFAP2A). This assay will be performed in ILC cells to maintain proper cellular context, using our unique library of 168 pre-clinical and clinical-stage serm/DS with diverse pharmacophores. Parallel evaluation of anti-proliferative activities against ILC cells will test whether disrupting context-specific ER:CO-regulator complexes improves efficacy. Specific aim 2 will validate ER:CO-regulator activities while revealing new serm/D-specific ER-interacting CO-regulators that correlate with improved anti-proliferative efficacy in ILC cells. Computational modeling will predict the structure- activity relationships that disfavor complex formation. Importantly, blinded evaluation of our findings by an independent investigator on our team will boost rigor and reproducibility. Together we will drive the future development of a novel class of serm/DS tailored to overcome anti-estrogen resistance in ILC.

Subawards

Subrecipient Amount Awarded
Loyola University Of Chicago Targeting context-specific estrogen receptor complexes to treat lobular breast cancer $88,434

Quick answers

Who received award R21CA307898?

R21CA307898 was awarded to The Regents Of The University Of Colorado by National Cancer Institute (National Institutes of Health) on July 13, 2026.

How much is award R21CA307898 worth?

$417,074 has been obligated on R21CA307898.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award